Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Metaboost Rx vs Trimi

Two GLP-1 desks, one scoreboard. We put Metaboost Rx and Trimi head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 316 · Grade C

Metaboost Rx

Visit Metaboost Rx Full brief →
vs
Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 60 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make Metaboost Rx a bad call — it's best for readers who want flat-rate semaglutide/tirzepatide plus a lower-dose microdose track for side-effect-sensitive patients. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
58
90
Supply Reliability
63
89
Transparency
72
91
Access Breadth
50
89
Clinical Oversight
65
88
Track Record
45
84
Metaboost RxBrief Score 60 · 89Trimi

Price, coverage & the tracker

Metaboost RxTrimi
Brief Score60/100 (C)89/100 (B+)
SemaglutideFrom $249/mo (compounded)$196/mo
TirzepatideFrom $299/mo (compounded)$296/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerNewnew to the tracker, no prior readingStableprice stable

Metaboost Rx: New to the tracker on 1 August 2026. The published line reads From $249/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.